JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 43(2009) N 3 p. 381-387;
F.A. Amosenko1,2, T.P. Kazubskaya2, O.E. Gromyko3, T.I. Matveeva1, E.L. Korchagina2, T.V. Nasedkina3, R.F. Garkavtseva2, V.N. Kalinin1,4

K-ras, BRCA1/2 , and CHEK2 mutations and loss of heterozygosity at 9p, 17p, and 18q in sporadic adenocarcinoma of the pancreas

1Research Centre for Medical Genetics, Russian Academy of Medical Sciences, Moscow, 115478, Russia
2Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, 115478, Russia
3Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia
4Department of General Surgery, Clinic Eppendorf, Hamburg University, Hamburg, 20246, Germany
Received - 2008-09-05; Accepted - 2008-10-14

The diagnostic significance of molecular markers was assessed for the most common somatic aberrations at the K-ras, TP53, CDKN2A, and MADH4 loci, as well as less common mutations of BRCA1, BRCA2, and CHEK2, arising in preinvasive stages of sporadic adenocarcinoma of the pancreas. The study was performed on paired primary pancreatic adenocarcinoma and normal pancreatic tissue specimens obtained from 37 Russian patients. Surgical adenocarcinoma specimens were subjected to manual microdissection. Mutations of K-ras codon 12 were found in 24 tumor specimens (0.65), but not in normal pancreatic tissue specimens. Mutations of BRCA1 (185delAG, 300T > G, 4153delA, 4158A > G, 5382insC), BRCA2 (695insT, 6174delT), and CHEK2 (1100delC) were not found. The informativeness of allelic losses did not differ significantly among the three tumor suppressor loci and was 60% for TP53 (GDB186817) and CDKN2A(D9S974 + D9S162) and 65.7% for MADH4 (D18S363 + D18S474) (t = 0.48). The CDKN2A locus had the highest LOH frequency of 0.95. For TP53 and MADH4 the LOH frequency was 0.62 and 0.70, respectively. In 80% of adenocarcinomas, at least one locus was characterized with LOH. The overall informativeness of the combined data on K-ras mutations and loss of heterozygosity at 9p, 17p, and 18q was 85.7%. Only 9% of the tumors were characterized with microsatellite instability.

pancreatic cancer, molecular markers, loss of heterozygosity (LOH), somatic mutations



JMB-FOOTER RAS-JOURNALS